Bristol Myers partner comes through on IL-12 effort. Now it's Rupert Vessey's turn at bat
- Mar 1, 2022
- 1 min read
Updated: Sep 13, 2022
Two years ago, Bristol Myers Squibb R&D boss Rupert Vessey unveiled one of the biggest cash deals he’d done, focusing on the high-risk, high-reward IL-12 target — doing it in a deal with repeat collaborator and NK cell engager player Dragonfly Therapeutics.
As part of that deal, Vessey handed over $475 million in near-term cash in exchange for a global license for Dragonfly’s extended half-life cytokine DF6002 — a monovalent, IL-12 immunoglobulin Fc fusion protein designed to spur a targeted immune response.
With $475M on the table for DF6002, Bristol Myers is clearly betting big on IL-12. I've been following NK cell engagers closely and would love to see how the extended half-life holds up in Phase 1. https://ai-for-animation.com
Rupert Vessey's IL-12 push with Dragonfly's DF6002 is a bold bet on NK cell engagers, and I'm curious how the extended half-life fusion protein performs in clinicals. Check out https://banana-nano.co
DF6002's extended half-life approach to IL-12 is a bold play for Bristol Myers. Rupert Vessey's $475M bet on Dragonfly shows serious conviction in NK cell engagers. I've been following IL-12 inhibitors closely — this one has real potential. https://veo3-ai.pro
DF6002's extended half-life approach to IL-12 could be a real differentiator in the NK engager space, especially after BMS's $475M bet. Rupert Vessey's track record with repeat collaborators like Dragonfly gives me pause — excited to see how the Phase data plays out. I've been tracking https://samaudiolab.com
The $475M bet on DF6002 shows real conviction in extended half-life IL-12. Rupert Vessey's been a smart partner since the BMS days—I'd love to see head-to-head data against other NK engagers. I've been following the clinical readouts closely https://aiphototemplate.com